37/#877 Hormonal biomarkers remain prognostic relevant within the molecular classification in endometrial cancer. (4th December 2022)

• Record Type: Journal Article
• Authors: Vrede, Stephanie; Weelden, Willem Jan; Bulten, Hans; Huvila, Jutta; Matias-Guiu, Xavier; Gil-Moreno, Antonio; Asberger, Jasmin; Sweegers, Sanne; Putten, Louis; Küsters-Vandevelde, Heidi; Eijkelenboom, Astrid; Reijnen, Casper; Colas, Eva; Weinberger, Vit; Snijders, Marc; Kruitwagen, Roy; Pijnenborg, Johanna
• Is Part Of: International journal of gynecological cancer. Volume 32(2022)Supplement 3
• Page Start: A42
• Page End: A42
• Publication Date: 2022-12-04
• Subjects: Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1136/ijgc-2022-igcs.81
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Objectives: The relevance of hormonal biomarkers in endometrial cancer (EC) has been well-established. A revised cut-off for estrogen receptor/progesterone receptor (ER/PR) expression into three subgroups was shown to improve prognostication, however, this has not been related to the four molecular subgroups. Therefore, we aimed to investigate the prognostic relevance of this three-tiered ER/PR model within the molecular subgroups in EC. Methods: A retrospective multicenter study within the European Network for Individualized Treatment (ENITEC) network was performed. ER/PR expression was classified into: high-risk (0–10%), intermediate-risk (20–80%) and low-risk (90–100%). The molecular subgroups were conducted based on Next Generation Sequencing, allocating patients into polymerase epsilon (POLE)-mutant, microsatellite instable (MSI), tumor protein (TP53)-mutated and no-specific molecular profile (NSMP). Results: A total of 387 patients were included with a median follow-up of 5.2-years. There were 8.3% (n=32) POLE-mutant, 22.5% (n=87) MSI, 13.7% (n=53) TP53-mutated and 55.6% (n=215) NSMP tumors. Among all molecular subgroups, patients with ER/PR 0–10% expression had significantly worse disease-specific survival (DSS) compared to ER/PR 20–80% or 90–100%. Interestingly within TP53-mutated, patients with ER/PR 90–100% expression showed an excellent DSS (100%) compared to ER/PR 20–80% and 0–10% ( figure 1 ). In multivariable analyses ER/PR 0–10%, TP53-mutated, lymphovascular space invasion and FIGO stage remained independent prognostic factors for reduced DSS (respectively, HR 2.59 (95%-CI 1.32–5.03) P=0.005, HR 2.71 (95%-CI 1.35–5.43) P=0.005, HR 2.27 (95%-CI 1.15–4.45) P=0.018, HR 4.42 (95%-CI 2.16–9.01) P<0.001). Conclusions: ER/PR expression remains prognostic relevant in all molecular subgroups, strengthened by the three-tiered cut-off. We therefore recommend routine evaluation of ER/PR expression in clinical practice.